Reduced-intensity conditioning (RIC) regimens allow allogeneic hematopoietic cell transplantation (HCT) in older patients with acceptable risks of treatment related mortality (TRM). Umbilical cord blood (UCB) has increased access to HCT for patients who do not have HLA-matched sibling donors (MSD). In this single institution study, we prospectively collected data on 98 consecutive patients (UCB 5 60, MSD 5 38) aged $ 55 years who received a RIC HCT for acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) between 2001 and 2009. All patients received HCT using RIC regimen because of their older age. All patients received cyclophosphamide, fludarabine and 200 cGy total body irradiation as conditioning and cyclosporine and mycophenolate mofetil as prophylaxis against graft-versus-host-disease (GVHD) (Brunstein et al, Blood 2007). Median age at HCT for UCB recipients was 61 (range, 55-70) years and for MSD recipients was 63 (range, 56-70) years. There was no difference in transplant year, CMV status, cytogenetic risk, disease status and HCT-comorbidity index (HCT-CI) scores between UCB and MSD cohorts. Among UCB recipients, 95% received HCT using two UCB units and 88% received 4/6 or 5/6 HLA matched units; the median cryopreserved nucleated cell dose was 3.6 Â 10 7 NC/kg. Overall survival at 3-years after HCT was 31% (95% CI, 19-44) for UCB and 37% (19-55) for MSD recipients (P 5 0.21). The 2-year cumulative incidence of relapse was 47% and 34% (P 5 0.19) and TRM was 25% and 25% (P 5 0.82), respectively. The cumulative incidence of acute GVHD (grades 2-4) for UCB and MSD recipients was 45% and 38% (P 5 0.19) and that for chronic GVHD at 2-years was 33% and 61% (P 5 0.04), respectively. In multivariate analyses, donor source had no impact on overall survival, leukemia free survival, relapse or TRM (Table) . In conclusion, RIC HCT using UCB is an acceptable alternative for older patients without a suitable MSD. 
RISK SCORE PREDICTS OUTCOME OF SECOND ALLOGENEIC HEMATO-POIETIC STEM CELL TRANSPLANTATION
Rezvani, K., Marin, D., Goldman, J.M., Kanfer, E., MacDonald, D., Dazzi, F., Milojkovic, D., Rahemtulla, A., Sargeant, J., Apperley, J., Szydlo, R. Hammersmith Hospital, London Increasing numbers of second allogeneic hematopoietic stem cell transplantation (allo-SCT) are being performed for patients who have previously undergone and failed an allogeneic or autologous stem cell transplant. We investigated whether the European Group for Blood and Marrow Transplantation (EBMT) risk score, previously established for chronic myeloid leukemia, could be used to predict outcome after second allo-SCT. We analyzed prognostic factors in 124 consecutive patients who underwent second transplants using allogeneic donors at our institution between 10/1985 and 02/2010. Patients with either a first autologous (N 5 64) or first allogeneic (N 5 60) SCT were included. Age of patient, disease stage, time interval from diagnosis to transplant, donor type, and donor-recipient gender combination were used to establish a score from 0 to 7 points, from which 3 groups were identified. The survival probability at 5 years decreased from 51.7% (95% Confidence interval [CI] 33-70%) for risk scores 0-3 (low, n 5 25), to 29.3% (95% CI, 17%-47%) for risk score 4 (medium, n 5 40), and only 10.4% (95%CI, 4%-24%) for risk scores 5-7 (high, n 5 57). Other factors investigated in univariate analysis included previous transplant type, myeloablative conditioning (Y/N), and interval between first and second SCT (median 20 months). In multivariate analysis, two factors were found to be important. An increased risk of death was associated with: a high risk score (Relative Risk 2.89, p 5 0.001) when compared with the low risk group and with a shorter interval between 1st and 2nd SCT (\ 20months), RR 1.55, p 5 0.05. Given that relapse after transplant can be a lethal situation and that select patients can remain alive and disease-free after second allogeneic transplant, a recent evidence-based guideline published by the American Society of Hematology has given the use of second allogeneic transplant after relapse a recommendation score of 1B. We propose that the five well-defined pre-transplant patient and donor characteristics that make up the EBMT risk score give an excellent risk estimate of outcome for second allogeneic HSCT. Taking into account both the interval between first and second SCT's and the risk score, can provide an accurate estimate of outcome and help in the selection of patient who are most likely to benefit from a second transplant.
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